Who's in favor of translational cell therapy for stroke: STEPS forward please?
A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.
Department of Neurology, Henry Ford Hospital, Detroit, MI, USA.
Michael
M
Chopp
Gary K
GK
Steinberg
Douglas
D
Kondziolka
Mei
M
Lu
Tonya M
TM
Bliss
Yi
Y
Li
David C
DC
Hess
Cesario V
CV
Borlongan
D000047:Academies and Institutes; D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic / Q000592:standards; D004353:Drug Evaluation, Preclinical / Q000592:standards; D006801:Humans; D009316:National Institutes of Health (U.S.); D017149:Private Sector; D033581:Stem Cell Transplantation; D020521:Stroke / Q000628:therapy*; D057170:Translational Research, Biomedical / Q000458:organization & administration*; D014481:United States; D014486:United States Food and Drug Administration